BioSpace News Archive

Rising number of people dealing with different neurological disorders is projected to create high demand opportunities for players in the global surgical power tools market in the forecast period of 2021 to 2031.

The expanding predominance of gynecological issues, like uterine irregularities, unusual uterine dying, uterine fibroids, and fruitfulness issues, is a key factor driving the market development.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Acepodia reported new interim data from an ongoing Phase 1 dose escalation study demonstrating feasibility with ACE1702, the company’s most advanced investigational antibody effector cell therapy, in development for patients with advanced HER2-positive tumors.

Shasqi presented interim data from its Phase 1 clinical study of SQ3370 in advanced sarcomas and other solid tumors, as well as additional non-clinical data at the European Society for Medical Oncology Congress, being held virtually on September 16-21, 2021.

Medivir AB invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented at the European Society for Medical Oncology congress.

Laekna Therapeutics reported positive results in two clinical studies for the treatment of early and late stages of prostate cancer respectively at the European Society for Medical Oncology Congress 2021.

Amgen announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer.

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol has made headway with COVID-19 treatment development in more broaden clinical trial patients permitted in inclusion severity as well as future marketing expansion by signing a new international MOU for cooperation and development of the new drugs in 23 European countries.